Core Viewpoint - EverQuote (EVER) shares have increased by 6.4% in the past four weeks, closing at $24.61, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $34.17, representing a 38.9% increase [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.79, where the lowest estimate of $30 indicates a 21.9% increase, and the highest estimate suggests a 54.4% surge to $38 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Market Sentiment - Analysts show increasing optimism about EverQuote's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 2.3% over the past month, with one estimate increasing and no negative revisions [12] - EverQuote holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]

Core Viewpoint - Verve Therapeutics (VERV) has shown a significant price increase of 25.4% over the past four weeks, with a mean price target of $24.75 indicating a potential upside of 367.9% from its current price of $5.29 [1] Price Targets and Analyst Consensus - The average price target for VERV includes estimates ranging from a low of $15 to a high of $39, with a standard deviation of $7.81, indicating variability among analysts [2] - The lowest estimate suggests an increase of 183.6%, while the most optimistic estimate points to a 637.2% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about VERV's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher [11] - Over the last 30 days, five estimates have moved higher with no negative revisions, leading to a 9.6% increase in the Zacks Consensus Estimate [12] - VERV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - HNI shares have increased by 8.8% over the past four weeks, closing at $47.26, with a mean price target of $69.50 indicating a potential upside of 47.1% [1] - The average price targets range from a low of $63 to a high of $80, with a standard deviation of $7.59, suggesting a consensus among analysts [2] - Analysts have shown increasing optimism regarding HNI's earnings prospects, with a 7.2% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - HNI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The positive trend in earnings estimate revisions is correlated with potential stock price movements, indicating a legitimate reason for expecting an upside [11] - Analysts' price targets, while often overly optimistic, can provide a starting point for further research into the stock's potential [9][10]

Core Viewpoint - Arcturus Therapeutics (ARCT) has seen a 7.5% increase in share price over the past four weeks, closing at $12.81, with analysts suggesting a potential upside of 371.4% based on a mean price target of $60.38 [1][12]. Price Targets and Analyst Estimates - The mean price target is derived from eight short-term estimates, with a standard deviation of $33.97, indicating variability among analysts [2]. - The lowest price target of $32 suggests a 149.8% increase, while the highest target of $140 indicates a potential surge of 992.9% [2]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction [9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates upward, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 42.1% over the past month, with four estimates rising and no negative revisions [12]. - ARCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as they often do not accurately predict stock price movements [3][7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Group 1 - Semtech (SMTC) shares have increased by 9.4% over the past four weeks, closing at $37.33, with a mean price target of $56.33 indicating a potential upside of 50.9% [1] - The average of 12 short-term price targets ranges from a low of $43 to a high of $68, with a standard deviation of $8.32, suggesting a potential increase of 15.2% to 82.2% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, with a 20.4% increase in the Zacks Consensus Estimate for the current year, indicating positive sentiment towards SMTC's earnings prospects [11][12] Group 2 - The Zacks Rank for SMTC is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] - While price targets are a common metric, they should be approached with skepticism as they can often mislead investors, and analysts may set overly optimistic targets due to business incentives [3][7][10] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]

Core Viewpoint - Backblaze, Inc. (BLZE) shows significant potential for upside, with a mean price target of $10.83 indicating a 90% upside from the current price of $5.70 [1] Price Targets - The average price target consists of six estimates ranging from a low of $8 to a high of $14, with a standard deviation of $1.94, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a potential increase of 40.4%, while the highest suggests a 145.6% upside [2] Analyst Sentiment - Analysts exhibit strong agreement regarding BLZE's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4%, with four estimates moving higher and no negative revisions [12] Zacks Rank - BLZE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - This rank, along with a strong externally-audited track record, serves as a conclusive indicator of the stock's potential upside in the near term [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them may not be wise due to the questionable ability and unbiasedness of analysts in setting these targets [3][7] - Analysts often set overly optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]

Pan American Silver (PAAS) closed the last trading session at $24.20, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.23 indicates a 29.1% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $4.44. While the lowest estimate of $26 indicates a 7.4% increase from the current price level, the most optimistic analyst ...

Core Viewpoint - Eastern Bankshares, Inc. (EBC) shows potential for significant upside, with a mean price target of $19.25 indicating a 30.2% increase from the current price of $14.78 [1] Price Targets and Analyst Consensus - The average price targets for EBC range from a low of $16 to a high of $23, with a standard deviation of $2.99, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates an 8.3% increase, while the highest suggests a 55.6% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about EBC's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 2.4% over the past month, with three estimates revised upward and no negative revisions [12] - EBC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Barrick Gold (B) shows potential for significant upside, with a mean price target of $24.39 indicating a 27.9% increase from the current price of $19.07 [1] Price Targets - The average of 16 short-term price targets ranges from a low of $21 to a high of $30.96, with a standard deviation of $2.90, suggesting a variability in estimates [2] - The lowest estimate indicates a 10.1% increase, while the highest suggests a 62.4% upside [2] Analyst Sentiment - Analysts are optimistic about Barrick Gold's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 2.2% over the past month, with three estimates revised higher and no negative revisions [12] Zacks Rank - Barrick Gold holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - The core viewpoint is that Benitec Biopharma Limited (BNTC) has significant upside potential, with a mean price target of $25.71 indicating an 83.9% increase from its current price of $13.98 [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $6.70, suggesting variability in analyst predictions; the lowest estimate is $17 (21.6% increase), while the highest is $35 (150.4% increase) [2] - Analysts show strong agreement on BNTC's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4][11] Group 2 - The Zacks Consensus Estimate for BNTC has increased by 15.6% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]